Co-expression of MAP17 and SGLT1 has also been reported as a biomarker associated with tumor expression and, in some cohorts, favorable prognosis (Perez et al., 2013; Du et al., 2022; Tampakis et al., 2021). The gene discussed is SLC5A1; the disease is neoplasm.